BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dulai PS, Singh S, Ohno-Machado L, Sandborn WJ. Population Health Management for Inflammatory Bowel Disease. Gastroenterology 2018;154:37-45. [PMID: 29122544 DOI: 10.1053/j.gastro.2017.09.052] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Singh S. PROMises Made, PROMises To Be Kept: Patient-Reported Outcome Measures in Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 2018;16:624-6. [DOI: 10.1016/j.cgh.2018.01.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Drescher H, Lissoos T, Hajisafari E, Evans ER. Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers. The Journal for Nurse Practitioners 2019;15:676-81. [DOI: 10.1016/j.nurpra.2019.07.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
3 Castellini G, Palamenghi L, Savarese M, Barello S, Leone S, Previtali E, Armuzzi A, Graffigna G. Patient Engagement in Health Management as a Mediator Between Perceived Risk and COVID-19 Related Distress in Patients With IBD: A Structural Equation Model. Front Psychiatry 2021;12:733544. [PMID: 34777043 DOI: 10.3389/fpsyt.2021.733544] [Reference Citation Analysis]
4 Chaparro M, Barreiro-de Acosta M, Benítez JM, Cabriada JL, Casanova MJ, Ceballos D, Esteve M, Fernández H, Ginard D, Gomollón F, Lorente R, Nos P, Riestra S, Rivero M, Robledo P, Rodríguez C, Sicilia B, Torrella E, Garre A, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP; EpidemIBD study group of GETECCU. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. Therap Adv Gastroenterol 2019;12:1756284819847034. [PMID: 31205485 DOI: 10.1177/1756284819847034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
5 Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol 2020;17:365-76. [PMID: 32303700 DOI: 10.1038/s41575-020-0293-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Lago-Hernandez C, Nguyen NH, Khera R, Loomba R, Asrani SK, Singh S. Cost-Related Nonadherence to Medications Among US Adults With Chronic Liver Diseases. Mayo Clin Proc 2021:S0025-6196(21)00255-X. [PMID: 34120754 DOI: 10.1016/j.mayocp.2021.02.026] [Reference Citation Analysis]
7 Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther 2020;52:481-91. [PMID: 32573825 DOI: 10.1111/apt.15876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Furey TS, Sethupathy P, Sheikh SZ. Redefining the IBDs using genome-scale molecular phenotyping. Nat Rev Gastroenterol Hepatol. 2019;16:296-311. [PMID: 30787446 DOI: 10.1038/s41575-019-0118-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
9 Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. Mol Cancer 2018;17:158. [PMID: 30447690 DOI: 10.1186/s12943-018-0900-3] [Cited by in Crossref: 136] [Cited by in F6Publishing: 129] [Article Influence: 34.0] [Reference Citation Analysis]
10 Nguyen NH, Koola J, Dulai PS, Prokop LJ, Sandborn WJ, Singh S. Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:1939-1948.e7. [PMID: 31470176 DOI: 10.1016/j.cgh.2019.08.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Singh S, Qian AS, Nguyen NH, Ho SKM, Luo J, Jairath V, Sandborn WJ, Ma C. Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. Inflamm Bowel Dis 2021:izab074. [PMID: 33988697 DOI: 10.1093/ibd/izab074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fudman DI, Perez-Reyes AE, Niccum BA, Melmed GY, Khalili H. Interventions to Decrease Unplanned Healthcare Utilization and Improve Quality of Care in Adults With Inflammatory Bowel Disease: A Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00928-9. [PMID: 34481951 DOI: 10.1016/j.cgh.2021.08.048] [Reference Citation Analysis]
13 Singh S, Brill JV, Proudfoot JA, Metcalfe L, Vu L, Sandborn WJ, Kosinski LR. Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 2018;16:1847-1850.e1. [DOI: 10.1016/j.cgh.2018.08.052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
14 Wu Q, Zhong J. Disease-related information requirements in patients with Crohn's disease. Patient Prefer Adherence 2018;12:1579-86. [PMID: 30214160 DOI: 10.2147/PPA.S169706] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Nguyen NH, Khera R, Dulai PS, Boland BS, Ohno-Machado L, Sandborn WJ, Singh S. National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States. Inflamm Bowel Dis 2021;27:1068-78. [PMID: 33051681 DOI: 10.1093/ibd/izaa266] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Lago-Hernandez C, Nguyen NH, Khera R, Loomba R, Asrani SK, Singh S. Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States. Hepatology 2021;74:1509-22. [PMID: 33772833 DOI: 10.1002/hep.31835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhang J, Lei H, Hu X, Dong W. Hesperetin ameliorates DSS-induced colitis by maintaining the epithelial barrier via blocking RIPK3/MLKL necroptosis signaling. Eur J Pharmacol 2020;873:172992. [PMID: 32035144 DOI: 10.1016/j.ejphar.2020.172992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
18 Jackson BD, De Cruz P. Quality of Care in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:479-89. [PMID: 30169698 DOI: 10.1093/ibd/izy276] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
19 Zhuang X, Li T, Li M, Huang S, Qiu Y, Feng R, Zhang S, Chen M, Xiong L, Zeng Z. Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019;25:1751-63. [DOI: 10.1093/ibd/izz188] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
20 Tse CS, Siegel CA, Weaver SA, Oliver BJ, Bresee C, van Deen WK, Melmed GY. Health Confidence Is Associated With Disease Outcomes and Health Care Utilization in Inflammatory Bowel Disease: A Nationwide Cross-sectional Study. Inflamm Bowel Dis 2021:izab313. [PMID: 34893849 DOI: 10.1093/ibd/izab313] [Reference Citation Analysis]
21 Chapman TP, Frias Gomes C, Louis E, Colombel J, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:73-84. [DOI: 10.1111/apt.15771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Georgy M, Negm Y, El-Matary W. Quality improvement in healthcare for patients with inflammatory bowel disease. Transl Pediatr 2019;8:77-82. [PMID: 30881901 DOI: 10.21037/tp.2019.01.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kinnucan J, Binion D, Cross R, Evans E, Harlen K, Matarese L, Mullins A, O’neal B, Reiss M, Scott FI, Weaver A, Rosenberg J. Inflammatory Bowel Disease Care Referral Pathway. Gastroenterology 2019;157:242-254.e6. [DOI: 10.1053/j.gastro.2019.03.064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
24 Richardson M, Ramsay LC, Bielecki JM, Berta W, Sander B. Systems thinking in health technology assessment: a scoping review. Int J Technol Assess Health Care 2021;37:e71. [PMID: 34162447 DOI: 10.1017/S0266462321000428] [Reference Citation Analysis]
25 Lopetuso LR, Scaldaferri F, Ianiro G, Bibbò S, Settanni CR, Papa A, Armuzzi A, Gasbarrini A, Cammarota G. The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center. Endosc Int Open 2020;8:E980-4. [PMID: 32617402 DOI: 10.1055/a-1183-3073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Coto P, Riestra S, Rozas P, Señaris A, Queiro R. Improving the standard of care for patients with spondyloarthritis-related immune inflammatory conditions: results of a Delphi study and proposal for early detection. Ther Adv Chronic Dis 2020;11:2040622320904295. [PMID: 32110287 DOI: 10.1177/2040622320904295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol 2018;113:1197-205. [PMID: 29925913 DOI: 10.1038/s41395-018-0144-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
28 Cohen-Mekelburg S, Rosenblatt R, Gold S, Shen N, Fortune B, Waljee AK, Saini S, Scherl E, Burakoff R, Unruh M. Fragmented Care is Prevalent Among Inflammatory Bowel Disease Readmissions and is Associated With Worse Outcomes. Am J Gastroenterol. 2019;114:276-290. [PMID: 30420634 DOI: 10.1038/s41395-018-0417-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
29 Guo K, Ren J, Gu G, Wang G, Gong W, Wu X, Ren H, Hong Z, Li J. Hesperidin Protects Against Intestinal Inflammation by Restoring Intestinal Barrier Function and Up-Regulating Treg Cells. Mol Nutr Food Res. 2019;63:e1800975. [PMID: 30817082 DOI: 10.1002/mnfr.201800975] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
30 Nguyen NH, Martinez I, Atreja A, Sitapati AM, Sandborn WJ, Ohno-Machado L, Singh S. Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review. Am J Gastroenterol 2021. [PMID: 34751673 DOI: 10.14309/ajg.0000000000001545] [Reference Citation Analysis]
31 Wei M, Gao X, Liu L, Li Z, Wan Z, Dong Y, Chen X, Niu Y, Zhang J, Yang G. Visceral Adipose Tissue Derived Exosomes Exacerbate Colitis Severity via Pro-inflammatory MiRNAs in High Fat Diet Fed Mice. ACS Nano 2020;14:5099-110. [PMID: 32275391 DOI: 10.1021/acsnano.0c01860] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 18.5] [Reference Citation Analysis]
32 Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2021;19:1377-1386.e5. [PMID: 32526341 DOI: 10.1016/j.cgh.2020.05.056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:709-718.e7. [PMID: 30012429 DOI: 10.1016/j.cgh.2018.07.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
34 Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. United European Gastroenterol J. 2020;8:775-781. [PMID: 32438878 DOI: 10.1177/2050640620929133] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
35 Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther 2020;51:553-64. [PMID: 31867766 DOI: 10.1111/apt.15609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
36 Michel HK, Boyle B, David J, Donegan A, Drobnic B, Kren C, Maltz RM, McKillop HN, McNicol M, Oates M, Dotson JL. The Pediatric Inflammatory Bowel Disease Medical Home: A Proposed Model. Inflamm Bowel Dis 2021:izab238. [PMID: 34562013 DOI: 10.1093/ibd/izab238] [Reference Citation Analysis]
37 Jackson B, Begun J, Gray K, Churilov L, Liew D, Knowles S, De Cruz P. Clinical decision support improves quality of care in patients with ulcerative colitis. Aliment Pharmacol Ther 2019;49:1040-51. [DOI: 10.1111/apt.15209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
38 Singh S. Evolution of Clinical Trials in Inflammatory Bowel Diseases. Curr Gastroenterol Rep 2018;20:41. [PMID: 30078058 DOI: 10.1007/s11894-018-0648-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
39 Limketkai BN, Singh S, Jairath V, Sandborn WJ, Dulai PS. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1828-37. [PMID: 31039246 DOI: 10.1093/ibd/izz081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
40 Bhattacharya S, Wong U, Cross RK. Telemedicine in the Management of Inflammatory Bowel Disease: An Update

]]>. SHTT 2020;Volume 7:9-17. [DOI: 10.2147/shtt.s195566] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Dorn SD. Gastroenterologists Without Borders: Using Virtual Care to Reach Beyond the Clinic Walls. Gastroenterology 2019;157:272-4. [DOI: 10.1053/j.gastro.2019.03.068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Chu L, Kannan V, Basit MA, Schaeflein DJ, Ortuzar AR, Glorioso JF, Buchanan JR, Willett DL. SNOMED CT Concept Hierarchies for Computable Clinical Phenotypes From Electronic Health Record Data: Comparison of Intensional Versus Extensional Value Sets. JMIR Med Inform 2019;7:e11487. [PMID: 30664458 DOI: 10.2196/11487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]